DNMT3A and acute myeloid leukemia: CD44v6 is aberrantly over-expressed in AML cell lines with DNMT3A or FLT3 mutations, and CD44v6 may be a target for CAR-T in AML patients with DNMT3A or FLT3 mutations [92].